BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tafinlar dabrafenib: Interim Phase I/II data

Interim data from 36 mCRC patients with V600 BRAF mutations in an open-label, U.S. and Australian Phase I/II trial showed that twice-daily 150 mg Tafinlar plus once-daily 2 mg Mekinist trametinib led to 1 complete response, 3 partial responses and 18 cases of stable disease. Median PFS was 3.5 months. The most frequent adverse events included pyrexia, nausea, fatigue, chills, vomiting, headache, peripheral edema, anemia and...

Read the full 318 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >